SaxaDapa is a fixed-dose combination (FDC) of sodium-glucose cotransporter-2 (SGLT-2) inhibitor Farxiga (dapagliflozin; AstraZeneca) and dipeptidyl peptidase-IV inhibitor Onglyza (dapagliflozin; AstraZeneca/Kyowa Hakko Kirin).
SaxaDapa is the second FDC containing an SGLT-2 inhibitor and a DPP-IV inhibitor approved to treat type 2 diabetes in the US and EU.
TABLE OF CONTENTS
4 PRODUCT PROFILES
4 SaxaDapa : Diabetes type 2
LIST OF FIGURES 9 Figure 1: SaxaDapa for type 2 diabetes – SWOT analysis
10 Figure 2: Datamonitor Healthcare drug assessment of SaxaDapa
11 Figure 3: Datamonitor Healthcare drug assessment scorecard for SaxaDapa compared to Januvia
LIST OF TABLES 4 Table 1: SaxaDapa drug profile
6 Table 2: SaxaDapa Phase III data in type 2 diabetes
9 Table 3: SaxaDapa Phase III trials in type 2 diabetes
Datamonitor Healthcare is part of Pharma intelligence
Datamonitor Healthcare is a trading division of Datamonitor Limited, a company registered in England and Wales with company number 2306113 whose registered office is 5 Howick Place, London, SW1P 1WG. VAT GB365462636. Datamonitor Limited is part of Informa PLC.
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726